Lessons from 10 years of interferon beta-1b (Betaferon®/Betaseron®) treatment

Journal of Neurology, Supplement

Volumn 250, Issue 4, 2003, Pages 3-8

  Bayas, Antonios ^a   Gold, Ralf ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Clinical trial; Interferon beta 1b; Multiple sclerosis; Review

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM PENTETATE MEGLUMINE; IBUPROFEN; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY; PLACEBO;

BRAIN ATROPHY; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; FLU LIKE SYNDROME; HUMAN; INJECTION PAIN; INJECTION SITE; INTERMETHOD COMPARISON; MULTIPLE SCLEROSIS; NERVE FIBER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; RELAPSE; REMISSION; SCORING SYSTEM; SKIN MANIFESTATION; SPASTICITY; TREATMENT OUTCOME; UNITED STATES;

ADULT; CLINICAL TRIALS; HUMANS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 0348223726     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Arnason BG and The IFNB Multiple Sclerosis Study Group and the UBC MS/ MRI Analysis Group (2003) High dose high frequency Betaferon treatment is effective in early stage relapsing remitting multiple sclerosis. Neurology 60(Suppl 1):A481
2. Barak Y, Achiron A (2002) Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 47:11-14
3. 1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 124:1396-1402
4. Bayas A, Rieckmann P (2000) Managing the adverse effects of interferon-beta therapy in multiple sclerosis. Drug Saf 22:149-159
5. Benatar M (2002) Interferon beta-1a and beta-1b for treatment of multiple sclerosis. Lancet 360:1428; author reply 1428-1429
6. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346: 158-164
7. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFN-beta-1a (Avonex) Dose-Comparison Study Investigators (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59:1507-1517
8. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357: 1576-1582
9. Dalton CM, Brex PA, Jenkins R, Fox NC, Miszkiel KA, Crum WR, O'Riordan JI, Plant GT, Thompson AJ, Miller DH (2002) Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 73:141-147
10. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58: 65-70
11. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453-1460
12. European Study Group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352: 1491-1497
13. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:169-178
14. Horowski R, Sturzebecher CS, Kapp JF (2001) Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis. Funct Neurol 16: 117-128
15. Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M (2000) Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. Am J Neuroradiol 21: 1034-1038
16. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multi-center, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
17. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
18. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898-904
19. Kappos L (2002) Interferon beta-1a and beta-1b for treatment of multiple sclerosis. Lancet 360:1428; author reply 1428-1429
20. Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F (2001) Final analysis of the European multicenter trial on IFN beta-1b in secondary-progressive MS. Neurology 57:1969-1975
21. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125: 2202-2212
22. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
23. nd Annual Meeting American Academy of Neurology, San Diego
24. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K (1999) Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol 46:850-859
25. Mohr DC, Goodkin DE, Likosky W, Gatto N, Neilley LK, Griffin C, Stiebling B (1996) Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler 2:222-226
26. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH (2000) The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 123:2256-2263
27. Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, MacManus DG, McDonald WI (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116:135-146
28. O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121:495-503
29. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59:1496-1506
30. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
31. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-1504
32. Quality Standards Subcommittee of the American Academy of Neurology (1994) Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 44:1537-1540
33. Rice GP, Ebers GC, Lublin FD, Knobler RL (1999) Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology 52:1893-1895
34. Rieckmann P, Toyka KV (1999) Escalating immunotherapy of multiple sclerosis. Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]. Eur Neurol 42: 121-127
35. Schering AG (2003) Data on file
36. SPECTRIMS Study Group (2001) Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon beta-1a in MS (SPECTRIMS). Randomized controlled trial of interferon beta-1a in secondary progressive MS: clinical results. Neurology 56:1496-1504
37. Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, McFarland HF (1995) The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 37:611-619
38. The Once Weekly Interferon for MS Study Group (1999) Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 53:679-686
39. The PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group, and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628-1636
40. Tornatore C, Bartlett D (2002) Tolerability of interferon beta-1b (Betaferon®/Betaseron®) can be significantly improved using both interferon-free needle and automated injection techniques. J Neurol 249(Suppl 1): I/205
41. Trapp BD, Ransohoff R, Rudick R (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12: 295-302
42. Walther EU, Hohlfeld R (1999) Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 53:1622-1627
43. Zhao GJ, Koopmans RA, Li DK, Bedell L, Paty DW (2000) Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group. Neurology 54:200-206